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Background {#sec005}
==========

Sleep is a natural, restorative, physiological process that is characterized by perceptual disengagement from and unresponsiveness to whatever going around, which must be reversible \[[@pone.0233849.ref001]\]. During sleep, most of the body's systems are in an anabolic state, helping to restore the immune, nervous, skeletal and muscular systems, which are vital processes that maintain mood, memory and cognitive function, and play important roles in daily functions \[[@pone.0233849.ref002], [@pone.0233849.ref003]\].

Sleep quality refers to how long an individual sleeps each night and how well he/she sleeps. Also, it includes how difficult it is for an individual to fall asleep, remain slumbering, and how many times he/she wakes up during the night. Moreover, it is a sense of being rested and refreshed after waking up from sleep \[[@pone.0233849.ref004]\].

Having a good sleep quality is an indicator of wellbeing whereas poor sleep quality results in increased co-morbidity, mortality, health care costs and poor quality of life of PLWHA \[[@pone.0233849.ref005]\]. Furthermore, poor sleep quality can cause an individual to feel tired the next day and may even be associated with long term risk of Alzheimer's disease \[[@pone.0233849.ref006]\].

Sleep disturbances impair the quality of life, cognitive function, and emotion of PLWHA that could lead to poor medication adherence \[[@pone.0233849.ref007]\]. It can induce various adverse outcomes in peoples living with HIV/AIDS (PLWHA), including diminished health-related quality of life, excessive day time sleepiness, and cognitive impairment \[[@pone.0233849.ref008]\]. In the HIV infected population, poor quality of sleep has been associated with, disease progression, side effects of medication, financial concerns, unemployment and inadequate knowledge about behaviors enhancing good sleep \[[@pone.0233849.ref009]\].

HIV/AIDS is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV), which interferes with the body's ability to fight against disease causing organisms \[[@pone.0233849.ref010]\]. It is one of the most devastating illnesses that human beings ever faced \[[@pone.0233849.ref011]\]. As of 2017, approximately 36.9 million peoples worldwide are living with HIV/AIDS. Sub-Saharan Africa is the most affected region, in 2017, an estimated 66% of new HIV infections occurred in this region \[[@pone.0233849.ref012]\]. Ethiopia is one of Sub-Saharan counties, reported a prevalence of 1.1% HIV/AIDS infection in 2016 among individuals aged between 15--49 \[[@pone.0233849.ref013]\].

In the United States of America, 50--70 million adults are suffering from sleeping problems \[[@pone.0233849.ref014]\]. Among them, insomnia and sleep apnea commonly dominate with a prevalence of 6%-10% and 10--25% respectively \[[@pone.0233849.ref015]\]. Sleep disturbances are thought to be common among HIV infected individuals in the US \[[@pone.0233849.ref016]\] and have a 40 to 70% prevalence of sleep disturbance and Patients with HIV were found to have a higher risk of sleep disturbances than the general population \[[@pone.0233849.ref017]\].

PLWHA are vulnerable to poor sleep quality as they suffer from the social stigma of the disease, unpleasant side effects of ARV medications including increased risk for metabolic syndromes \[[@pone.0233849.ref018]\]. Depression often considered as a logical outcome in peoples living with HIV/AIDS and consequently may lead to and exacerbates sleep disturbance \[[@pone.0233849.ref019]\]. Also, addictive drug use is associated with sleep disturbances in persons living with HIV/AIDS \[[@pone.0233849.ref020]\]. There is a controversy regarding the association of duration since HIV diagnosis with sleep quality, in which some studies state that short duration since diagnosis is negatively associated with sleep quality \[[@pone.0233849.ref017]\]; whereas others discussed that individuals with long durations since HIV status known are more likely to have diminished sleep quality \[[@pone.0233849.ref021], [@pone.0233849.ref022]\].

Despite all the above evidence in developed and middle-income countries, little is known in low-income countries, especially in Ethiopia. So, the current study tried to fill this gap and examined the prevalence and associated factors of poor quality of sleep among people living with HIV/AIDS attending ART clinic at Hawassa University Comprehensive Specialized Hospital.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

An institutional-based cross-sectional study was conducted to examine the prevalence and associated factors of poor quality of sleep among PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital (HUCSH) from May1-30, 2019. Hawassa University Comprehensive Specialized hospital is located in Hawassa city, SNNPR, which is 275 km far from Addis Ababa. Beyond other inpatient and outpatient medical services, the hospital provides ART services for PLWHA.

Population {#sec008}
----------

All PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital were source population. PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital ART clinic during the data collection period were the study population. Individual ART client attending ART clinic at Hawassa University Comprehensive Specialized Hospital was the study unit.

PLWHA attending Hawassa University Comprehensive Specialized Hospital ART clinic with age 18 years and above were included in the study but those with a severe medical condition (unconscious or critically ill) and unable to communicate due to hearing difficulty were excluded from the study.

Sample size and sampling technique {#sec009}
----------------------------------

The sample size was determined using a single population proportion formula considering assumption (Z = 1.96, d = 0.05, and P = 50%). Then, adding a 10% non-response rate, the final estimated sample size was 422. Among the total ART clients currently being enrolled in ART service, 422 study participants were selected through systematic random sampling technique using sampling fraction; K = 6. The sampling fraction (K) was obtained by dividing the total ART clients who have follow-up at Hawassa University comprehensive specialized hospital (n = 2533) by the sample size, 2533/422 which is 6. The first individual was selected using a lottery method, and the rest were selected at a regular interval (every 6^th^).

Measurements and data collection technique {#sec010}
------------------------------------------

Data were collected by four psychiatry nurses using interviewer administered technique. During data collection daily base supervision was conducted by one MSc psychiatry professional to check for completeness of data collection tool.

Sleep quality was assessed by using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-rated scale which examined Sleep Quality and disturbances over a 1 month time interval. The tool mainly addresses seven sleep components: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of hypnotics, and daytime dysfunction during the last month. The total PSQI score is then calculated by summing-up the seven component scores, giving an overall score ranging from 0 to 21. The score \>5 points indicates poor sleep quality \[[@pone.0233849.ref023]\]. For the current study the internal consistency of PSQI was found Cronbach's alpha α = 0.76.

The hospital anxiety and depression scale (HADS) was used to assess anxiety and depression. It has been validated in Ethiopia and its internal consistency was α = 0.78 for anxiety, α = 0.76 for depression subscales and α = 0.87 for full scale. It has two subscales: the anxiety subscale (HADS-A) and the depression subscale (HADS-D). Each subscale contains seven items, giving a total of 14 items in the HADS. It has cutoff point ≥ 8 for each subscale suggestive of depression and anxiety \[[@pone.0233849.ref024]\]. For the current study the internal consistency was Cronbach's alpha α = 0.81 for full scale.

Social support was measured by using 3 items Oslo social support scale (OSS-3) which is classified as poor social support (3--8 OSS score), intermediate social support (9--11 OSS score), and strong social support (12--14 OSS score) \[[@pone.0233849.ref025]\]. For the current study the internal consistency of OSS-3 was Cronbach's alpha α = 0.73. Current substance use: assessing the use of any substance (alcohol, tobacco, cigarette and other) in the last 3 months. Ever use of the substance was assessed if a study participant used any substance (alcohol, tobacco, cigarette and other) at least once in his lifetime.

Monthly income was categorized using the 2015 World Bank poverty line classification. World Bank re-established the international poverty line; from 1.25 US \$- 1.9 US \$ (1.9\*29.06\*30 = 1656 Ethiopian birr (ETB)) monthly income considered as the poverty line. Below poverty line: \< 1656 ETB and above poverty line: ≥ 1656 ETB \[[@pone.0233849.ref026]\].

Variables and data analysis {#sec011}
---------------------------

The dependent variable was quality of sleep (poor/good) and the independent variables were sociodemographic factors (age, sex, marital status, occupation, religion, educational status, income), clinical factors (CD4 count, WHO clinical stage of HIV/AIDS, duration since HIV/AIDS diagnosis, ART drug type, presence of co-morbid medical illness), Substance use (ever use/current use), psychosocial factors (depression, anxiety, social support) and environmental factors (noise disturbance).

Data entry and analysis was conducted using SPSS 22 software. Bivariable logistic regression analysis was conducted to identify independent factors associated with poor quality of sleep. Possible confounding (important variable which have a hidden effect on the outcome) variables were entered into a multivariable logistic regression model to identify the association of each independent variable with poor quality of sleep. In the final model, variables with a p-value of less than 0.05 declared as statistically significant, and AOR with 95% CI was calculated to determine the strength of association. Model fitness was checked using the Hosmer and Lemeshow test, and it was found to be 0.71. Multi-collinearity was checked by the variance inflation factor (VIF) and tolerance.

Ethics approval and consent to participate {#sec012}
------------------------------------------

Ethical clearance was obtained from the Institutional Review Board (IRB) of Hawassa University, college of medicine and health sciences. The data collectors clearly explained the aim of the study for every study participant. Written consent was sought from individual ART client who agreed to participate. Participants who can't read and write gave a fingerprint to indicate consent. Each participant was informed that they have the right to refuse or discontinue participation at any time they want. All participants were randomly selected without any discrimination on any ground. Filled out questionnaires were carefully handled, and all access to results was kept strictly within the members of the research team.

Results {#sec013}
=======

Socio-demographic characteristics {#sec014}
---------------------------------

Out of 422 estimated study participants, 389 were included in the analysis, making a response rate of 92.2%. The mean age of respondents was 38.2 (±9.7) years. From the total study participants, 231 (59.4%) were females and 261 (67%) were married. The mean estimated monthly income of patients was 1612.7 (±1349) Ethiopian birr (ETB) (**[Table 1](#pone.0233849.t001){ref-type="table"}**).

10.1371/journal.pone.0233849.t001

###### Socio-demographic characteristics of PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital, SNNPR, Ethiopia, 2019 (n = 389).

![](pone.0233849.t001){#pone.0233849.t001g}

  Variable             Category                   Frequency (%)
  -------------------- -------------------------- ---------------
  Age                  18--24                     53 (13.6)
  25--54               233 (59.9)                 
  55--64               85(21.9)                   
  \>65                 18(4.6)                    
  Sex                  Male                       158 (40.6)
  Female               231 (59.4)                 
  Religion             Orthodox                   177 (45.5)
  Protestant           155 (39.8)                 
  Muslim               51 (13.1)                  
  Others               6 (1.5)                    
  Marital status       Married                    261 (67)
  Single               46 (11.8)                  
  Divorced             38 (9.8)                   
  Widowed              44 (11.3)                  
  Educational status   Unable to read and write   49 (12.6)
  Primary              164 (42.2)                 
  Secondary            110 (28.3)                 
  College/University   66 (17)                    
  Occupation           Civil servant              58 (14.9)
  Merchant             109 (28)                   
  Day worker           107 (27.5)                 
  Student              16 (4.1)                   
  House wife           66 (17)                    
  Unemployed           23 (5.9)                   
  Others               10 (2.6)                   
  Monthly income       \<1656ETB                  245 (63)
  ≥1656 ETB            144 (37)                   

Clinical characteristics {#sec015}
------------------------

Out of 389 respondents, 267 (68.6%) were in stage I for WHO clinical staging. Regarding the time since HIV diagnosis, 314 (80.7%) have a duration above 1 year and 259 (66.6%) of respondents have CD4 count ≥500 cells/ml. 209 (53.7%) study participants used EFV based combination ART drug type, and 106(27.2%) have a co-morbid medical illness (**[Table 2](#pone.0233849.t002){ref-type="table"}**).

10.1371/journal.pone.0233849.t002

###### Clinical characteristics of PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital, SNNPR, Ethiopia, 2019 (n = 389).

![](pone.0233849.t002){#pone.0233849.t002g}

  Clinical factors                                                          Frequency and (%)
  ------------------------------------------------------------------------- -------------------
  WHO clinical stages                                                       
  Stage I                                                                   267 (68.6)
  Stage II                                                                  96 (24.7)
  Stage III                                                                 20 (5.1)
  Stage IV                                                                  6 (1.5)
  Time since HIV diagnosis                                                  
  ≤1 year                                                                   75 (19.3)
  \>1 year                                                                  314 (80.7)
  CD4 count                                                                 
  \<200 cells/ml                                                            11 (2.8)
  200--499 cells/ml                                                         119 (30.6)
  ≥500 cells/ml                                                             259 (66.6)
  ART drug Type                                                             
  EFV-based                                                                 209 (53.7)
  Non-EFV                                                                   180 (46.3)
  Presence of any comorbid chronic medical illness (DM, Ca, HTN or other)   
  No                                                                        283 (72.8)
  Yes                                                                       106 (27.2)

**Abbreviation:** DM: Diabetes Mellitus, Ca: Cancer, HTN: Hypertension, ART: Antiretroviral Therapy, EFV: Efavirenz

Substance use {#sec016}
-------------

Out of 389 respondents, 156 (40.1%) and 102 (26.2%) used at least one substance in their lifetime and within the last 3 months respectively (**[Fig 1](#pone.0233849.g001){ref-type="fig"}**).

![Types of substances used by study participants attending ART clinic at HUCSH, SNNPR, Ethiopia, 2019 (n = 389).](pone.0233849.g001){#pone.0233849.g001}

Psychosocial and environmental factors {#sec017}
--------------------------------------

Based on the Hospital Anxiety and Depression Scale, 124(31.9%) and 119(30.6%) of respondents had anxiety and depression respectively. 167(42.9%) of participants received poor social support. Out of the total respondents, 66(17%) complained about the experience of noise disturbance during their sleeping time.

Quality of sleep {#sec018}
----------------

The prevalence of poor quality of sleep among PLWHA was 57.6%. The mean total PSQI score of individuals with poor quality of sleep was 8.43(±2.74) as compared to 3.21 (±1.47) of those with good quality of sleep (**[S1 Table](#pone.0233849.s001){ref-type="supplementary-material"}**).

Factors associated with poor quality of sleep {#sec019}
---------------------------------------------

From the total variables included in the multivariable logistic regression analysis, five variables were found to be statistically significant (P\<0.05). Accordingly, age (55--64 and \>64), average monthly income (**\<**1656 ETB), having anxiety, having depression and poor social support were found to be significantly associated with poor sleep quality (**[Table 3](#pone.0233849.t003){ref-type="table"}**).

10.1371/journal.pone.0233849.t003

###### Bivariable and multivariable logistic regression of factors associated with poor quality of sleep among PLWHA attending ART clinic at Hawassa University Comprehensive Specialized Hospital, SNNPR, Ethiopia, 2019 (n = 389).

![](pone.0233849.t003){#pone.0233849.t003g}

  Variable                       Category                 Poor Sleep Quality   COR (95%CI)       AOR (95%CI)                                                  
  ------------------------------ ------------------------ -------------------- ----------------- ------------------------------------------------------------ ---------------------------------------------------------
  Age                            18--24                   23                   30                1                                                            1
  25--54                         114                      119                  1.25 (0.69,2.3)   1.4 (0.6, 3.4)                                               
  55--64                         72                       13                   7.2 (3.2, 16.1)   **5.7(1.9, 17.8)**[\*](#t003fn001){ref-type="table-fn"}      
  ≥ 65                           15                       3                    6.5(1.6, 25.2)    **6.6(1.2, 36.9)**[\*](#t003fn001){ref-type="table-fn"}      
  Marital status                 Married                  142                  121               1                                                            1
  Single                         29                       15                   1.6(0.86, 3.27)   1.6 (0.5, 5.0)                                               
  Divorced                       26                       12                   2.1(1.01, 4.46)   1.1(0.4, 3.0)                                                
  Widowed                        27                       17                   1.37(0.7, 2.64)   0.9(0.34, 2.2)                                               
  Educational status             Unable to read & write   36                   13                2.8(1.25,6.14)                                               0.5(0.13, 1.6)
  Primary                        101                      63                   1.56(0.8,2.78)    0.6(0.26, 1.7)                                               
  Secondary                      54                       56                   1.0(0.54,1.84)    0.8(0.35, 2.2)                                               
  College/university             33                       33                   1                 1                                                            
  Occupation                     Civil servant            19                   39                1                                                            1
  Merchant                       59                       50                   2.4 (1.24, 4.7)   2.7(1.01, 7.3)                                               
  Day worker                     71                       34                   4.29(2.16,8.5)    1.83(0.57,5.8)                                               
  Student                        11                       5                    4.5(1.37,14.9)    2.28(0.32,16.2)                                              
  House wife                     36                       30                   2.46 (1.2, 5.1)   1.27(0.37,4.3)                                               
  Unemployed                     19                       6                    6.5 (2.2, 18.9)   3.4 (0.9, 13.2)                                              
  Others                         9                        1                    18.5(2.1,25.6)    5.6 (0.3, 9.6)                                               
  Monthly income                 **\<**1656 ETB           163                  82                2.7(1.77,4.13)                                               **2.17(1.06,4.4)**[\*](#t003fn001){ref-type="table-fn"}
  ≥1656 ETB                      61                       83                   1                 1                                                            
  Anxiety                        No                       116                  149               1                                                            1
  Yes                            108                      16                   8.6(4.86,15.4)    **4.4(2.12, 9.2)**[\*\*](#t003fn002){ref-type="table-fn"}    
  Depression                     No                       119                  151               1                                                            1
  Yes                            105                      14                   9.5(5.19,17.4)    **4.97 (2.28, 10)**[\*\*](#t003fn002){ref-type="table-fn"}   
  WHO stages of HIV/AIDS         Stage I                  131                  136               1                                                            1
  Stage II                       74                       22                   3.49(2.05,5.9)    0.77(0.18, 3.4)                                              
  Stage III & IV                 19                       7                    2.82(1.14, 6.9)   0.17(0.03, 1.2)                                              
  Duration since HIV diagnosis   ≤1 year                  39                   36                1                                                            1
  \>1 year                       185                      129                  1.41(0.85, 2.3)   0.86(0.43, 1.7)                                              
  CD4 count                      \<200 cells/ml           9                    2                 5.1(1.07,23.8)                                               1.9 (0.22, 18.2)
  200--499 cells /ml             93                       26                   4.01(2.44, 6.6)   3.0 (0.7, 13.2)                                              
  ≥500 cells/ml                  122                      137                  1                 1                                                            
  ART drug type                  EFV-based                136                  73                1.86 (1.24,2.8)                                              1.7 (0.9, 3.04)
  Non EFV-based                  88                       92                   1                 1                                                            
  Chronic medical illness        No                       147                  136               1                                                            1
  Yes                            77                       29                   2.45(1.5, 3.99)   1.6 (0.8, 3.3)                                               
  Lifetime substance use         No                       120                  113               1                                                            1
  Yes                            104                      52                   1.88(1.2, 2.87)   1.3(0.6, 2.8)                                                
  Current substance use          No                       151                  136               1                                                            1
  Yes                            73                       29                   2.27(1.4, 3.7)    1.03(0.4, 2.6)                                               
  Social support                 Poor                     127                  40                5.8(3.02,11.3)                                               **2.9(1.16, 7.3)**[\*](#t003fn001){ref-type="table-fn"}
  Moderate                       77                       90                   1.57(0.8, 2.97)   1.2(0.5, 2.8)                                                
  Good                           19                       35                   1                 1                                                            

**\***Significant association **(**P-value \<0.05)

**\*\***Significant association **(**P-value \<0.01)**, Abbreviation:** COR: Crudes Odds Ratio, AOR: Adjusted Odds Ratio, CI: Confidence Interval, ART: Anti-Retroviral Therapy, ETB: Ethiopian Birr

Discussion {#sec020}
==========

In the current study, the prevalence of poor sleep quality was 57.6% (95% CI: 54.72, 60.48). The result is somewhat in agreement with the result reported from Mexico which is 58.9% \[[@pone.0233849.ref022]\]. However, the prevalence in the current study was lower than the study conducted in Nigeria which is 59.3% \[[@pone.0233849.ref017]\]. The finding in the current study was higher than the result reported from South Africa which showed that the prevalence of poor sleep quality was 52% \[[@pone.0233849.ref027]\], 46.2% in University of Calabar teaching Hospital, South Nigeria \[[@pone.0233849.ref028]\], Iran 47.5% \[[@pone.0233849.ref029]\], China 43.1% \[[@pone.0233849.ref030]\], Brazil 46.7% \[[@pone.0233849.ref031]\], France 47% \[[@pone.0233849.ref021]\], Southern US 40% \[[@pone.0233849.ref032]\], John Hopkins Medical Institution USA 56% \[[@pone.0233849.ref033]\], another study in USA 46.1% \[[@pone.0233849.ref016]\] and Taiwan 27.4% \[[@pone.0233849.ref034]\]. These discrepancies might be due to various factors including differences in the geographical area, socio-cultural variation, characteristics of study participants and the inclusion and exclusion criteria used.

An individual living with HIV/AIDS age between 55--64 years was 5.7 times more likely to experience poor sleep quality compared to the younger (18--24 years) individual. Also, study participants with age ≥ 65 were 6.6 times more likely to experience poor quality of sleep compared with those with younger age groups. This implication might be related to various factors including age-related immunity deterioration, dropping of growth hormone levels, which is known to facilitate deep sleep, psychological and socio-economic factors including retirement from jobs result in a poor quality of sleep. Also, as an individual gets older, the neurological receptors that connect with sleep signaling chemicals weaken, which results in the brain face a long time figuring out when individuals are tired \[[@pone.0233849.ref035]\]. The current finding was consistent with the study conducted in China \[[@pone.0233849.ref036]\].

Individuals below the poverty line (\<1656 ETB) were 2 times more likely to experience poor quality of sleep compared with those above poverty lines. This might be related to some negative emotions posed by survival pressure over low-income earners might result in a poor quality of sleep. Also, individuals with higher socioeconomic status have been hypothesized to get positive social, psychological, and economic skills that protect against the effect of hardship \[[@pone.0233849.ref037]\] which would protect sleep problems. This finding is in agreement with the study reported in China \[[@pone.0233849.ref036]\].

Our study also revealed that the presence of both anxiety and depression increases the possibility of experiencing poor quality of sleep compared with their counterpart. This might be due to the linkages between sleep, emotional regulation and alteration in the Hypothalamic-pituitary-adrenal axis implication of psychopathology and sleep-wake cycle. Also, the presence of insomnia symptoms was higher among individuals who have anxiety and depression which results in poor sleep quality \[[@pone.0233849.ref038]\]. The result is in agreement with the studies conducted in the USA \[[@pone.0233849.ref016]\], Mexico \[[@pone.0233849.ref021]\] and Iran \[[@pone.0233849.ref039]\].

Lastly, our study result suggested, individuals who received poor social support to be 2.9 times more likely to develop poor quality of sleep. Social support is thought to promote sleep quality by providing a safe context in which close family or friends protect sleepers from enemies or other threats \[[@pone.0233849.ref040]\]. The current finding was in line with the study conducted in Mexico \[[@pone.0233849.ref021]\].

Limitation of the study {#sec021}
-----------------------

One limitation of our study is that it's cross-sectional nature, which is weak to evaluate the cause-effect relationship. Lack of a control group limited our study's ability to characterize the sleep pattern of people with HIV/AIDS in contrast to the general population. Also, since only 1.5% of the samples in the current study were classified as stage IV, the finding can't be generalized for study participants at severe HIV stage.

Conclusion {#sec022}
==========

The prevalence of poor quality of sleep among PLWHA was high (57.6%), which indicates desperate life of individuals living with HIV/AIDS in Ethiopia. Average monthly income, age, anxiety, depression, and social support were found to be significantly associated with poor sleep quality. Health care professionals working at the ART clinic need to regularly assess the sleep pattern of ART clients, give psychoeducation on prevention and management of sleep pattern problems. Special consideration has to be given to those with age \>55 years, having poor social support, having depression and anxiety, and individuals living below the poverty line.

Supporting information {#sec023}
======================

###### Sleep quality and its components score of PLWHA attending ART clinic at Hawassa University Comprehensive specialized Hospital, SNNPR, Ethiopia, 2019 (n = 389).

(DOCX)

###### 

Click here for additional data file.
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study entitled "Quality of sleep and associated factors among people living with HIV/AIDS attending ART clinic at Hawassa University comprehensive specialized Hospital, Hawassa, SNNPR, Ethiopia" assessed an important topic of sleep on people with HIV/AIDS attending ART clinic. I am impressed by the high response rate for the study and I do think that the study adds something to the current literature; especially the study investigated understudied population. However, grammatical errors and editing errors can be found in the manuscript. For example, in the Abstract sentence: Data was entered and analyzed using SPSS version 22, Adjusted odds ratio (AOR) with 95% CI, was estimated to assess the strength of associations and variables with p-value \<0.05 were considered statistically significant. Several errors are easily observed: "Data were"; "SPSS version 22, adjusted odds ratio". It is not the reviewer's responsibility to point out all the errors and the authors may consider asking help from a native English speaker to improve the quality. Moreover, some uncommonly used abbreviations are directly used without explanation (e.g., HTN, ETB). The authors should provide a full spell-out for these abbreviations when they are firstly mentioned. I have additionally specific comments below.

1\. The following two references are talking about the sleep among people with HIV/AIDS. The authors should incorporate them in the Introduction.

<https://www.ncbi.nlm.nih.gov/pubmed/28735919>

<https://www.ncbi.nlm.nih.gov/pubmed/31739231>

2\. In the sentence "Among the total ART clients currently being enrolled in ART service, 422 study participants were selected using a systematic random sampling technique (K=6)." I cannot understand what K=6 means here.

3\. Please incorporate the Variables section into the Data process and analysis section.

4\. What is the meaning of "Daily base supervision was conducted by one mental health professional specialist"? Do the authors mean the psychiatry nurses were under supervision by mental health professional specialist to collect data? If so, what kind of supervision is it?

5\. As the instruments are all self-report nature, I wonder what exactly the psychiatry nurses administer the survey.

6\. Please provide the internal consistency information of the instruments (PSQI, HADS, and OSS-3) for the present study sample.

7\. I wonder whether the PSQI and the OSS-3 have an Ethiopia version. The authors have explicitly mentioned that Ethiopia version of HADS, but not for the PSIQ and OSS-3.

8\. In Data processing and analysis section, please define what a possible confounder variable is.

9\. In the first paragraph of the Discussion section, I wonder whether all the compared countries used the same instrument with the same cutoff point (i.e., using PSQI with a cutoff at 5) to indicate the poor sleep quality. Also, it is unclear whether all the mentioned studies assessing people with HIV/AIDS. Please clarify.

10\. Avoid using "besides" throughout the manuscript.

11\. Please comment on how the study results can be generalized to other population with HIV/AIDS. Specifically, the sample was relatively healthy in the HIV stages; therefore, the results may not be applicable to people with severe HIV stage.

12\. Please comment on how the prevalence rate of poor sleep quality found in the present study can be generalized to the Ethiopia. Also, please revise the sentence "Also, it is better if HUCSH ART staffs carefully assess the sleeping pattern of PLWHA and special consideration has to be given to those with age \>55 years, having poor social support, having depression and anxiety and those living below the poverty line." I think that the authors should not narrow down their implications to only one hospital. I understand that the authors may not want to overgeneralize their results; however, implication for a hospital only does not provide impact to the healthcare field.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Editor and Reviewers

We would like to thank the Editorial team and the reviewer for their valuable and very helpful comments. We have tried to address comments carefully and have made numerous changes to the manuscript which we hope meet an approval. We are also happy to make any further changes and additions. Please find below a copy of our response to the reviewer\'s comments on our manuscript reference number PONE-D-20-10185.

Kind regards,

Asres Bedaso (corresponding author) 

Reviewer \#1

1\. The study entitled "Quality of sleep and associated factors among people living with HIV/AIDS attending ART clinic at Hawassa University comprehensive specialized Hospital, Hawassa, SNNPR, Ethiopia" assessed an important topic of sleep on people with HIV/AIDS attending ART clinic. I am impressed by the high response rate for the study and I do think that the study adds something to the current literature; especially the study investigated understudied population. However, grammatical errors and editing errors can be found in the manuscript. For example, in the Abstract sentence: Data was entered and analyzed using SPSS version 22, Adjusted odds ratio (AOR) with 95% CI, was estimated to assess the strength of associations and variables with p-value \<0.05 were considered statistically significant. Several errors are easily observed: "Data were"; "SPSS version 22, adjusted odds ratio". It is not the reviewer's responsibility to point out all the errors and the authors may consider asking help from a native English speaker to improve the quality. Answer: Thanks for the comments. We have addressed the mentioned spelling and grammatical errors. Also, we have addressed other spelling and grammatical errors in the manuscript. We have used online spelling and grammar software to correct all spelling and grammar related problems.

2\. Moreover, some uncommonly used abbreviations are directly used without explanation (e.g., HTN, ETB). The authors should provide a full spell-out for these abbreviations when they are firstly mentioned. I have additionally specific comments below.

Answer: Thanks for the comments, we have addressed the problem in the revised manuscript.

3\. The following two references are talking about the sleep among people with HIV/AIDS. The authors should incorporate them in the Introduction.

<https://www.ncbi.nlm.nih.gov/pubmed/28735919>

<https://www.ncbi.nlm.nih.gov/pubmed/31739231>

Answer: I would really thank the reviewer for suggesting the literatures. We have included the literatures in the revised manuscript.

4\. In the sentence "Among the total ART clients currently being enrolled in ART service, 422 study participants were selected using a systematic random sampling technique (K=6)." I cannot understand what K=6 means here.

Answer: Thanks again for the comment, we have clearly explained it in the revised manuscript.

5\. Please incorporate the Variables section into the Data process and analysis section.

Answer: Thanks, we incorporated your comment in the revised manuscript.

6\. What is the meaning of "Daily base supervision was conducted by one mental health professional specialist"? Do the authors mean the psychiatry nurses were under supervision by mental health professional specialist to collect data? If so, what kind of supervision is it?

Answer: See the revised manuscript, we have addressed your comment.

7\. As the instruments are all self-report nature, I wonder what exactly the psychiatry nurses administer the survey.

Answer: We have used interviewer administered technique as a data collection technique, not self-administered technique. This was one of the reason for the high response rate.

8\. Please provide the internal consistency information of the instruments (PSQI, HADS, and OSS-3) for the present study sample.

Answer: Thanks for the comment, we have included the internal consistency information for PSQI, HADS and OSS-3. See the revised manuscript.

9\. I wonder whether the PSQI and the OSS-3 have an Ethiopia version. The authors have explicitly mentioned that Ethiopia version of HADS, but not for the PSIQ and OSS-Answer: PSQI and OSS-3 was not validated in Ethiopia but we have translated the English version of both tools in to Amharic by language experts. Also back translation was done by language experts who can speak both Amharic and English. Finally before the final data collection, pre-test was done to see the internal consistency of the tools and to see if there was any collinearity.

10\. In Data processing and analysis section, please define what a possible confounder variable is.

Answer: Thanks for the comment. We have defined the confounding variable in the revised manuscript.

11\. In the first paragraph of the Discussion section, I wonder whether all the compared countries used the same instrument with the same cutoff point (i.e., using PSQI with a cutoff at 5) to indicate the poor sleep quality. Also, it is unclear whether all the mentioned studies assessing people with HIV/AIDS. Please clarify.

Answer: The studies we included in discussion section used similar tool to assess Sleep quality and similar cut of point.

12\. Avoid using "besides" throughout the manuscript.

Answer: We have corrected based on your comment. See the revised manuscript.

13\. Please comment on how the study results can be generalized to other population with HIV/AIDS. Specifically, the sample was relatively healthy in the HIV stages; therefore, the results may not be applicable to people with severe HIV stage.

Answer: Thanks again for the delightful insight and suggestions. Since only 1.5% of the samples were classified as stage IV, it is difficult to generalize for those at severe HIV stage, rather we preferred to mention this as a limitation. See the revised manuscript.

14\. Please comment on how the prevalence rate of poor sleep quality found in the present study can be generalized to the Ethiopia.

Answer: See the revised manuscript. We have made revisions in our conclusion.

15\. Also, please revise the sentence "Also, it is better if HUCSH ART staffs carefully assess the sleeping pattern of PLWHA and special consideration has to be given to those with age \>55 years, having poor social support, having depression and anxiety and those living below the poverty line."

Answer: We have made modifications based on your comments. You can see the revised manuscript.

16\. I think that the authors should not narrow down their implications to only one hospital. I understand that the authors may not want to overgeneralize their results; however, implication for a hospital only does not provide impact to the healthcare field.

Answer: We have made some revision on the mentioned issue. See the revised manuscript.

Cheers!!

Asres Bedaso
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have well addressed all my previous comments. I am satisfied with the revision and glad to recommend publication.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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